Indrayani Biotech Postpones Partly Paid-up Rights Issue Schedule
Indrayani Biotech Ltd has announced a decision by its Rights Issue Committee to postpone the schedule for its partly paid-up Rights Issue. The company confirmed the outcome of the committee meeting held on June 22, 2026.The postponement pertains to the timeline of the Rights Issue, which was previously scheduled with specific dates and subsequent extensions. Originally, the issue was set to open on Wednesday, May 27, 2026, and close on Thursday, June 25, 2026. This schedule was subsequently extended, intending for the closure date to be Friday, July 24, 2026.
As decided by the Rights Issue Committee, the entire schedule is now postponed until further notice. The company stated that a separate notification will be issued with the revised issue opening and closing dates once they are finalized.
Despite the delay in scheduling, Indrayani Biotech confirmed that all terms related to the offer price and the rights entitlement ratio will remain unchanged from those previously approved by the Rights Issue Committee.
The updated issue documents will be made available on the company's website and on the stock exchange platform upon the finalization of the revised issue schedule.
Stock Price Movement
For Indrayani Biotech Ltd, the market settled at ₹10.55 after trading today, showing a decline of 0.57%. Throughout the session, shares traded within an intraday range that stretched from a low of ₹10.50 to a high of ₹11.14.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.